However, inhibitors only block FAP activity and do not cause harm to FAP+ cells; therefore, when used in RA-FLS, the effect of such drugs may not be satisfactory because other proteins such as CD90 and CD34 are still expressed on the surface of FLS. This evidence concerns the gene FAP and rheumatoid arthritis.